JP2016521280A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521280A5 JP2016521280A5 JP2016512061A JP2016512061A JP2016521280A5 JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5 JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016512061 A JP2016512061 A JP 2016512061A JP 2016521280 A5 JP2016521280 A5 JP 2016521280A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphoma
- pharmaceutical composition
- composition according
- cell
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 9
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 8
- -1 quinazolinone compound Chemical class 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 5
- 206010025310 Other lymphomas Diseases 0.000 claims 5
- 208000003950 B-Cell Lymphoma Diseases 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 210000004369 Blood Anatomy 0.000 claims 3
- 206010026798 Mantle cell lymphomas Diseases 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 201000003444 follicular lymphoma Diseases 0.000 claims 3
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000009899 Burkitt Lymphoma Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 210000003800 Pharynx Anatomy 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- 101700006234 AKT1 Proteins 0.000 claims 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims 1
- 210000003719 B-Lymphocytes Anatomy 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N Benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 210000000988 Bone and Bones Anatomy 0.000 claims 1
- 210000000133 Brain Stem Anatomy 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 206010067184 Burkitt's leukaemia Diseases 0.000 claims 1
- 210000003169 Central Nervous System Anatomy 0.000 claims 1
- 210000003679 Cervix Uteri Anatomy 0.000 claims 1
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 210000003238 Esophagus Anatomy 0.000 claims 1
- 210000001508 Eye Anatomy 0.000 claims 1
- 210000001280 Germinal Center Anatomy 0.000 claims 1
- 210000003128 Head Anatomy 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000000867 Larynx Anatomy 0.000 claims 1
- 206010024324 Leukaemias Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 210000001165 Lymph Nodes Anatomy 0.000 claims 1
- 208000008968 Lymphoma, Large-Cell, Anaplastic Diseases 0.000 claims 1
- 210000000214 Mouth Anatomy 0.000 claims 1
- KXBDTLQSDKGAEB-UHFFFAOYSA-N N-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 KXBDTLQSDKGAEB-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 Neck Anatomy 0.000 claims 1
- 210000001672 Ovary Anatomy 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 210000004011 Plasma Cells Anatomy 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 210000002307 Prostate Anatomy 0.000 claims 1
- 210000000664 Rectum Anatomy 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 210000002784 Stomach Anatomy 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 210000001550 Testis Anatomy 0.000 claims 1
- 210000001685 Thyroid Gland Anatomy 0.000 claims 1
- 210000003932 Urinary Bladder Anatomy 0.000 claims 1
- 210000004291 Uterus Anatomy 0.000 claims 1
- 206010047802 Waldenstrom's macroglobulinaemias Diseases 0.000 claims 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 210000000038 chest Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 201000009251 multiple myeloma Diseases 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 101710039033 pkbA Proteins 0.000 claims 1
- 230000000306 recurrent Effects 0.000 claims 1
- 230000001850 reproductive Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000002992 thymic Effects 0.000 claims 1
Claims (20)
- 置換キナゾリノン化合物を含む、癌を治療するための医薬組成物であって、該置換キナゾリノン化合物が、癌を有する患者に、N-(3-(5-フルオロ-2-(4-(2-メトキシエトキシ)フェニルアミノ)ピリミジン-4-イルアミノ)フェニル)アクリルアミド、又はその医薬として許容し得る塩と併用して投与されるように用いられることを特徴とする、前記医薬組成物。
- 前記癌が血液由来の癌である、請求項1記載の医薬組成物。
- 前記血液由来の癌がリンパ腫、白血病又は多発性骨髄腫である、請求項2記載の医薬組成物。
- 前記リンパ腫が非ホジキンリンパ腫である、請求項3記載の医薬組成物。
- 前記非ホジキンリンパ腫がびまん性大細胞型B細胞リンパ腫(DLBCL)、濾胞性リンパ腫(FL)、急性骨髄性白血病(AML)、マントル細胞リンパ腫(MCL)又はALK+未分化大細胞型リンパ腫である、請求項4記載の医薬組成物。
- 前記非ホジキンリンパ腫がびまん性大細胞型B細胞リンパ腫(DLBCL)である、請求項4記載の医薬組成物。
- 前記リンパ腫がB細胞リンパ腫である、請求項3記載の医薬組成物。
- 前記B細胞リンパ腫がびまん性大細胞型B細胞リンパ腫、バーキットリンパ腫/白血病、マントル細胞リンパ腫、縦隔(胸腺)大細胞型B細胞リンパ腫、濾胞性リンパ腫、辺縁帯リンパ腫、及びリンパ形質細胞リンパ腫/ワルデンシュトレームマクログロブリン血症から選択されるB細胞非ホジキンリンパ腫である、請求項7記載の医薬組成物。
- 前記B細胞非ホジキンリンパ腫が難治性B細胞非ホジキンリンパ腫である、請求項8記載の医薬組成物。
- 前記B細胞非ホジキンリンパ腫が再発性B細胞非ホジキンリンパ腫である、請求項8記載の医薬組成物。
- 前記B細胞リンパ腫が慢性リンパ性白血病又は小リンパ球性リンパ腫である、請求項7記載の医薬組成物。
- 前記びまん性大細胞型B細胞リンパ腫が胚中心B細胞様びまん性大細胞型B細胞リンパ腫又は活性化B細胞様びまん性大細胞型B細胞リンパ腫である、請求項8記載の医薬組成物。
- 前記リンパ腫がT細胞リンパ腫である、請求項3記載の医薬組成物。
- 前記癌が頭部、頸部、眼、口腔、咽喉、食道、気管支、喉頭、咽頭、胸部、骨、肺、結腸、直腸、胃、前立腺、膀胱、子宮、子宮頸部、乳房、卵巣、精巣又は他の生殖器官、皮膚、甲状腺、血液、リンパ節、腎臓、肝臓、膵臓及び脳又は中枢神経系の癌である、請求項1記載の医薬組成物。
- 前記癌がmTOR、PI3K又はAktキナーゼ及びその突然変異体又はアイソフォームを含む経路に関連する癌である、請求項1記載の医薬組成物。
- 前記置換キナゾリノン化合物をN-(3-(5-フルオロ-2-(4-(2-メトキシエトキシ)フェニルアミノ)ピリミジン-4-イルアミノ)フェニル)アクリルアミドのベシル酸塩と併用して投与する、請求項1記載の医薬組成物。
- 前記置換キナゾリノン化合物が表A〜Gの化合物である、請求項1記載の医薬組成物。
- 前記患者に、抗CD20抗体がさらに投与されるように用いられることを特徴とする、請求項1記載の医薬組成物。
- 抗CD20抗体がリツキシマブである、請求項18記載の医薬組成物。
- 前記置換キナゾリノン化合物が、
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819384P | 2013-05-03 | 2013-05-03 | |
| US61/819,384 | 2013-05-03 | ||
| US201361908635P | 2013-11-25 | 2013-11-25 | |
| US61/908,635 | 2013-11-25 | ||
| PCT/US2014/036520 WO2014179661A1 (en) | 2013-05-03 | 2014-05-02 | Methods for treating cancer using combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521280A JP2016521280A (ja) | 2016-07-21 |
| JP2016521280A5 true JP2016521280A5 (ja) | 2017-06-15 |
Family
ID=50842385
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512061A Pending JP2016521280A (ja) | 2013-05-03 | 2014-05-02 | 併用療法を用いて癌を治療する方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9119854B2 (ja) |
| EP (1) | EP2991651A1 (ja) |
| JP (1) | JP2016521280A (ja) |
| TW (1) | TW201534305A (ja) |
| WO (1) | WO2014179661A1 (ja) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008039489A2 (en) | 2006-09-26 | 2008-04-03 | Celgene Corporation | 5-substituted quinazolinone derivatives as antitumor agents |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| ES2814952T3 (es) | 2012-09-04 | 2021-03-29 | Celgene Corp | Isotopólogos de 3-(5-amino-2-metil-4-oxoquinazolin-3(4H)-il) piperidina-2-6-diona y métodos de preparación de los mismos |
| EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | HETEROARYL COMPOUNDS AND USES THEREOF |
| US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| US10272083B2 (en) * | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| EP3166635A1 (en) * | 2014-07-11 | 2017-05-17 | Celgene Corporation | Combination therapy for cancer |
| EP3304076A4 (en) * | 2015-06-02 | 2018-12-19 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| EP3316888A1 (en) * | 2015-07-02 | 2018-05-09 | Celgene Corporation | Combination therapy for treatment of hematological cancers and solid tumors |
| CA2999179A1 (en) * | 2015-09-25 | 2017-03-30 | Celgene Corporation | Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| CA3010794A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| MX2018008421A (es) * | 2016-01-08 | 2019-12-09 | Celgene Corp | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. |
| WO2017120422A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Antiproliferative compounds, and their pharmaceutical compositions and uses |
| EP3399979B9 (en) | 2016-01-08 | 2023-10-04 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| KR20200054046A (ko) * | 2018-11-09 | 2020-05-19 | 한국화학연구원 | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 |
| CN113151358B (zh) * | 2020-12-31 | 2024-02-20 | 洛阳市中心医院（郑州大学附属洛阳中心医院） | Znf382稳定转染的弥漫大b细胞淋巴瘤细胞株构建方法及应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003208415B2 (en) | 2002-02-14 | 2009-05-28 | Immunomedics, Inc. | Anti-CD20 antibodies and fusion proteins thereof and methods of use |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| PL2143795T3 (pl) | 2005-03-31 | 2011-12-30 | Biomedics Inc | Przeciwciało monoklonalne skierowane przeciwko CD20 |
| AU2006252733A1 (en) | 2005-06-02 | 2006-12-07 | Astrazeneca Ab | Antibodies directed to CD20 and uses thereof |
| WO2008039489A2 (en) * | 2006-09-26 | 2008-04-03 | Celgene Corporation | 5-substituted quinazolinone derivatives as antitumor agents |
| ES2527297T3 (es) | 2007-07-31 | 2015-01-22 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos para CD20 humano y método para utilizar los mismos |
| KR101234436B1 (ko) | 2007-09-05 | 2013-02-18 | 로슈 글리카트 아게 | 유형 ⅰ 및 유형 ⅱ 항-ｃｄ２０ 항체를 사용하는 병용 치료요법 |
| MY157495A (en) | 2007-09-26 | 2016-06-15 | Celgene Corp | 6-,7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| JP2011526299A (ja) | 2008-06-27 | 2011-10-06 | アビラ セラピューティクス， インコーポレイテッド | ヘテロアリール化合物およびそれらの使用 |
| JP5645816B2 (ja) | 2009-05-25 | 2014-12-24 | 国立大学法人東京工業大学 | 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物 |
| US20110223157A1 (en) | 2010-03-12 | 2011-09-15 | Schafer Peter H | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
| AU2011289604C1 (en) * | 2010-08-10 | 2016-04-21 | Celgene Avilomics Research, Inc. | Besylate salt of a BTK inhibitor |
| EP2683384B1 (en) | 2011-03-11 | 2015-12-09 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione |
| MX353482B (es) * | 2011-04-29 | 2018-01-16 | Celgene Corp | Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor. |
| AR088570A1 (es) * | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton |
-
2014
- 2014-05-02 EP EP14727340.3A patent/EP2991651A1/en not_active Withdrawn
- 2014-05-02 WO PCT/US2014/036520 patent/WO2014179661A1/en active Application Filing
- 2014-05-02 TW TW103115872A patent/TW201534305A/zh unknown
- 2014-05-02 JP JP2016512061A patent/JP2016521280A/ja active Pending
- 2014-05-02 US US14/268,439 patent/US9119854B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016521280A5 (ja) | ||
| JP2016516821A5 (ja) | ||
| MX2017012411A (es) | Co-cristales de un inhibidor de tirosina cinasa de bruton. | |
| JP2016523974A5 (ja) | ||
| MY194405A (en) | Dihydropyrimidine compounds and uses thereof in medicine | |
| PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
| MX2021012478A (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. | |
| JP2015508103A5 (ja) | ||
| AR107751A1 (es) | Composiciones de forma de dosificación que comprenden un inhibidor de tirosina cinasa de bruton | |
| JP2015187156A5 (ja) | ||
| CU20130133A7 (es) | Sales de 2,3- dihidroimidazo[1,2- c] quinazolinas sustituda | |
| MX2016014639A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso para tratar cancer. | |
| EA201790995A1 (ru) | ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ | |
| RU2021102805A (ru) | 4,6-ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРАЗИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| JP2019070012A5 (ja) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| US20060281755A1 (en) | Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators | |
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| JP2019514854A5 (ja) | ||
| BR112019006228A2 (pt) | tratamento de câncer de próstata | |
| PH12016500301A1 (en) | Formulations of (s)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione | |
| MX2017012430A (es) | Formas solvatadas de un inhibidor de tirosina quinasa de bruton. | |
| JP2016529285A5 (ja) | ||
| ES2688809T3 (es) | Combinaciones de compuestos inhibidores de AKT y MEK para tratar el cáncer | |
| JP2017514806A5 (ja) |